CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Enoxaparin Higher DoseWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1392 Lower-dose prophylactic anticoagulation Wiki 1.00
drug2193 Sampling (EDTA blood, pharyngeal and nose swabs, bronchoalveolar lavage ,urine) Wiki 1.00

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D060085 Coinfection NIH 0.71
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Randomized Trial of Anticoagulation Strategies in COVID-19

This is a randomized open label trial to compare effectiveness of two dosing regimens currently used for prevention of clotting events in COVID-19 positive inpatients. Both doses and routes of anticoagulation regimens are currently used in COVID-19 positive inpatients at NYU Langone Health.

NCT04359277 COVID-19 Drug: Enoxaparin Higher Dose Drug: Lower-dose prophylactic anticoagulation

Primary Outcomes

Measure: Composite incidence of: all-cause mortality, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, stroke, or shock

Time: 30 days

Secondary Outcomes

Description: 0 = Uninfected; no viral RNA detected Ambulatory = Asymptomatic; viral RNA detected = Symptomatic: Independent = Symptomatic: assistance needed Hospitalized: Mild disease = Hospitalized; no oxygen therapy = Hospitalized; oxygen by mask or nasal prongs = Hospitalized; oxygen by NIV or High flow = Intubation & Mechanical ventilation, pO2/FIO2 >/= 150 or SpO2/FIO2 = Mechanical ventilation pO2/FIO2 < 150 (SpO2/FIO2 <200) 9 = Mechanical ventilation pO2/FIO2 < 150 and vasopressors, dialysis 10 = Dead N (%)

Measure: Score on WHO Ordinal Scale

Time: 30 days

Description: AKI is defined as any of the following (Not Graded): Increase in SCr by X0.3 mg/dl (X26.5 lmol/l) within 48 hours; or Increase in SCr to X1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or- Urine volume o0.5 ml/kg/h for 6 hours.

Measure: Incidence of acute kidney injury (KDIGO criteria for Acute Kidney Injury (AKI))

Time: 30 days

Measure: Requirement of invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)

Time: 30 days

Description: Measured by troponin and NTproBNPlevels

Measure: Cardiac injury

Time: 30 days

Description: measured by D-dimer and fibrinogen levels

Measure: Hypercoagulability

Time: 30 days

Description: Platelet Count >100 x 109/L 0 Points >50 - <100 x 109/L 1 Point <50 x 109/L 2 Points Increase in Fibrin-related Markers [D Dimers] No change 0 Points Moderate rise 2 Points Strong rise 3 Points Prothrombin Time [PT] Prolongation 3 s or less 0 Points >3 s but <6 s 1 Point >6 s 2 Points Fibrinogen [Clauss] Level >1.0 g/L 0 Points <1.0 g/L 1 Point Score 0-8 Interpretation of Score < 5 Suggestive of non-overt/low grade DIC. Repeat in 1-2 days. ≥ 5 Laboratory evidence consistent with overt DIC.

Measure: Disseminated Intravascular Coagulation (DIC) Score

Time: 30 days

Measure: Length of Hospital Stay

Time: 30 days


No related HPO nodes (Using clinical trials)